Detalhe da pesquisa
1.
Ovarian cancer mutational processes drive site-specific immune evasion.
Nature
; 612(7941): 778-786, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36517593
2.
Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes.
Gynecol Oncol
; 182: 32-38, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38246044
3.
Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
Gynecol Oncol
; 186: 104-109, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38640773
4.
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Gynecol Oncol
; 180: 35-43, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38041901
5.
The highs and lows of serous ovarian cancer.
Cancer
; 129(17): 2613-2620, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366225
6.
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies.
Cancer
; 129(13): 2004-2012, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36951509
7.
Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level - A Memorial Sloan Kettering Cancer Center study.
Gynecol Oncol
; 170: 46-53, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36621269
8.
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
Gynecol Oncol
; 170: 93-101, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36669327
9.
Ten-year conditional probability of survival for patients with ovarian cancer: A new metric tailored to Long-term survivors.
Gynecol Oncol
; 169: 85-90, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36521353
10.
Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial.
Gynecol Oncol
; 171: 23-30, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36804618
11.
Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol
; 176: 69-75, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37454565
12.
Germline drivers of gynecologic carcinosarcomas.
Gynecol Oncol
; 174: 34-41, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37149903
13.
Safety and feasibility of therapeutic anticoagulation for newly diagnosed venous thromboembolism in women who undergo neoadjuvant chemotherapy for advanced ovarian cancer.
Int J Gynecol Cancer
; 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38088180
14.
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Int J Gynecol Cancer
; 33(9): 1331-1344, 2023 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37591609
15.
Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
Gynecol Oncol
; 164(1): 12-17, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34763937
16.
Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.
Curr Oncol Rep
; 24(11): 1549-1555, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35962920
17.
Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation.
Int J Gynecol Cancer
; 32(12): 1576-1582, 2022 12 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36368707
18.
Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.
Gynecol Oncol
; 163(1): 36-40, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34312001
19.
Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol
; 160(1): 51-55, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33213899
20.
A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
Gynecol Oncol
; 160(1): 71-76, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33139041